BioNxt moves sublingual semaglutide film into active pharmaceutical development
BioLife separately won a U.S. patent for an effervescent oral peptide delivery technology intended to protect peptide molecules through the digestive tract.
MH
By Maren Holt · Senior Reporter, GLP-1
Oct 7 20:00 ETSource: Raleigh News & Observer
The wire
- 01BioNxt Solutions advanced a sublingual semaglutide oral thin-film into active pharmaceutical development in 2026, describing it as the first use of a broader GLP-1 oral dissolving film platform.
- 02Needle aversion limits uptake: a 2022 PLOS ONE study of 2,098 participants found 63.2% reported needle phobia, averaging 5.7 out of 10 in fear intensity, with 94.1% citing non-invasive alternatives as a solution.
- 03Both programs remain preclinical or early development, and an oral semaglutide tablet is already marketed; the article says the next 12 to 24 months will separate serious contenders from press-release science.
From the source
Read at newsobserver.comNeedle phobia is keeping some people from peptides. Could needle-free strip options change that?
If needle fear is what has kept someone in your household from starting a peptide for weight loss or diabetes, the delivery options are about to expand. Semaglutide and its peers are mainstream now, and drugmakers are racing to deliver these peptides without a syringe, using dissolving films or strips, effervescent tablets and other oral formats. How quickly those alternatives reach pharmacies wil
